7:07 AM ET
8-K
Business Update
Rocket Pharmaceuticals Business Update
Rocket Pharmaceuticals announced alignment with the FDA on the pivotal Phase 2 trial design for RP-A501 in Danon disease, including a 12-patient pivotal population and 12-month co-primary endpoints. The FDA's review of initial safety data from the first three patients supports continued enrollment and dosing under a modified protocol, with completion of dosing expected by mid-2027.
- Counterparty
- FDA